JO3261B1 - مشتق بيريدين أحادي الحلقة - Google Patents

مشتق بيريدين أحادي الحلقة

Info

Publication number
JO3261B1
JO3261B1 JOP/2014/0039A JOP20140039A JO3261B1 JO 3261 B1 JO3261 B1 JO 3261B1 JO P20140039 A JOP20140039 A JO P20140039A JO 3261 B1 JO3261 B1 JO 3261B1
Authority
JO
Jordan
Prior art keywords
group
hydrogen atom
present
alkoxy
pharmaceutically acceptable
Prior art date
Application number
JOP/2014/0039A
Other languages
English (en)
Inventor
Ohashi Isao
Okada Toshimi
Nagao Satoshi
Funasaka Setsuo
Tanaka Keigo
Nakatani Yusuke
Yamane Yoshinobu
Karoji Yuki
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Application granted granted Critical
Publication of JO3261B1 publication Critical patent/JO3261B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

يتعلق الاختراع الحالي بتقديم مركب جديد له نشاط مثبط لـ FGFR أو ملح مقبول صيدلانيا منه، وتركيبة صيدلانية تتضمنه. بصفة خاصة، يقدم الاختراع الحالي مركب ممثل بالصيغة التالية (I) أو ملح مقبول صيدلانيا منه: حيث n تمثل 0 الى 2؛ A تمثل مجموعة أريلين أو مجموعة أريلين غير متجانسة؛ G تمثل رابطة فردية، ذرة أكسجين أو -CH 2 - ؛ E تمثل سيكل غير متجانسة غير عطرية تتضمن نيتروجين؛ R1 تمثل مجموعة ألكوكسي، مجموعة ألكوكسي ألكوكسي أو ما شابه ذلك؛ R2 تمثل ذرة هيدروجين، ذرة هالوجين، مجموعة هيدروكسيل، مجموعة ألكيل، مجموعة هيدروكسي ألكيل، مجموعة سيكليك غير متجانسة غير عطرية تتضمن نيتروجين أو ما شابه ذلك؛ و R3 تمثل ذرة هيدروجين، مجموعة ألكيل، مجموعة ألكوكسي أو ما شابه ذلك، بشرط أنه عندما تكون E تمثل حلقة أزيتيدين و R2 أو تكون R3 موجودة على ذرة نيتروجين على حلقة الأزيتيدين، R2 أو R3 لا تمثل ذرة هيدروجين.
JOP/2014/0039A 2013-02-20 2014-02-18 مشتق بيريدين أحادي الحلقة JO3261B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361766922P 2013-02-20 2013-02-20

Publications (1)

Publication Number Publication Date
JO3261B1 true JO3261B1 (ar) 2018-09-16

Family

ID=51351646

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2014/0039A JO3261B1 (ar) 2013-02-20 2014-02-18 مشتق بيريدين أحادي الحلقة

Country Status (35)

Country Link
US (1) US8933099B2 (ar)
EP (1) EP2960238B1 (ar)
JP (2) JP5600229B1 (ar)
KR (1) KR102050128B1 (ar)
CN (1) CN105073730B (ar)
AR (1) AR094812A1 (ar)
AU (1) AU2014219811B2 (ar)
BR (1) BR112015019790B1 (ar)
CA (1) CA2901585C (ar)
CL (1) CL2015002311A1 (ar)
CY (1) CY1119220T1 (ar)
DK (1) DK2960238T3 (ar)
ES (1) ES2628495T3 (ar)
HR (1) HRP20170873T1 (ar)
HU (1) HUE032931T2 (ar)
IL (1) IL240623B (ar)
JO (1) JO3261B1 (ar)
LT (1) LT2960238T (ar)
ME (1) ME02755B (ar)
MX (1) MX361870B (ar)
MY (1) MY178760A (ar)
NZ (1) NZ711101A (ar)
PE (1) PE20151509A1 (ar)
PH (1) PH12015501813A1 (ar)
PL (1) PL2960238T3 (ar)
PT (1) PT2960238T (ar)
RS (1) RS56064B1 (ar)
RU (1) RU2645352C2 (ar)
SG (1) SG11201506488WA (ar)
SI (1) SI2960238T1 (ar)
SM (1) SMT201700288T1 (ar)
TW (4) TWI672296B (ar)
UA (1) UA116794C2 (ar)
WO (1) WO2014129477A1 (ar)
ZA (1) ZA201505941B (ar)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9951047B2 (en) 2014-08-18 2018-04-24 Eisai R&D Management Co., Ltd. Salt of monocyclic pyridine derivative and crystal thereof
EP3275442B1 (en) * 2015-03-25 2021-07-28 National Cancer Center Therapeutic agent for bile duct cancer
WO2017104739A1 (ja) * 2015-12-17 2017-06-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 乳がん治療剤
CN107098884A (zh) * 2016-02-19 2017-08-29 中国科学院上海药物研究所 一类取代的氨基吡啶类化合物及其制备和用途
BR112020003849A2 (pt) * 2017-10-12 2020-09-08 Eisai R&D Management Co., Ltd. composição farmacêutica compreendendo inibidor seletivo de tirosina quinase fgfr
BR112020017922A2 (pt) 2018-03-28 2020-12-22 Eisai R&D Management Co., Ltd. Agente terapêutico para carcinoma hepatocelular
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
BR112022020786A2 (pt) * 2020-04-17 2022-11-29 Eisai R&D Man Co Ltd Agente terapêutico de câncer de mama
EP4151212A4 (en) 2020-07-31 2024-04-10 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer
US20230330081A1 (en) 2020-10-28 2023-10-19 Eisai R&D Management Co., Ltd. Pharmaceutical composition for treating tumors
MX2024001504A (es) * 2021-08-31 2024-02-27 Eisai R&D Man Co Ltd Metodo para producir un derivado de piridina monociclico.
EP4361139A4 (en) * 2021-08-31 2025-08-20 Eisai R&D Man Co Ltd PROCESS FOR PRODUCING SYNTHETIC INTERMEDIATE OF MONOCYCLIC PYRIDINE DERIVATIVE
JP2025507196A (ja) * 2022-03-18 2025-03-13 上▲海▼▲潤▼石医▲薬▼科技有限公司 置換のアミノ６員窒素複素環式化合物の塩及びその結晶形、製造方法と応用
WO2025061013A1 (zh) * 2023-09-18 2025-03-27 上海润石医药科技有限公司 包含杂芳基氧基萘类化合物的药物组合物及其制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
HU230302B1 (hu) 2000-10-20 2015-12-28 Eisai R&D Management Co., Ltd. Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények
JP4071636B2 (ja) 2001-04-03 2008-04-02 エーザイ・アール・アンド・ディー・マネジメント株式会社 シクロオクタノン誘導体およびシクロデカノン誘導体、およびその用途
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
MXPA05001536A (es) * 2002-08-30 2005-04-19 Eisai Co Ltd Derivados aromaticos que contienen nitrogeno.
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
KR100864393B1 (ko) 2003-04-10 2008-10-20 에프. 호프만-라 로슈 아게 피리미도 화합물
US20050256154A1 (en) 2004-05-04 2005-11-17 Kin-Chun Luk 4-Amino-thieno[3,2-c]pyridine-7-carboxylic acid amides
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
FR2883286B1 (fr) 2005-03-16 2008-10-03 Sanofi Aventis Sa NOUVEAUX DERIVES D'IMIDAZO[1,5-a]PYRIDINES, INHIBITEURS DE FGFs, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
EP2270000B1 (en) * 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
MEP3808A (xx) 2005-12-21 2010-02-10 Novartis Ag Derivati pirimidinil aril uree kao fgf inhibitori
JP2009184924A (ja) 2006-05-31 2009-08-20 Eisai R & D Management Co Ltd 生物学的試薬用化合物
TW200811134A (en) 2006-07-12 2008-03-01 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1891955A1 (en) 2006-07-24 2008-02-27 Sanofi-Aventis Use of 1,2,3-substituted indolizine derivatives, inhibitors of FGFs, for the preparation of a medicament intended for the treatment of degenerative joint diseases
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8513276B2 (en) 2006-12-22 2013-08-20 Astex Therapeutics Limited Imidazo[1,2-a]pyridine compounds for use in treating cancer
HRP20150642T1 (hr) 2006-12-22 2015-08-14 Astex Therapeutics Limited BICIKLIÄŚKE HETEROCIKLIÄŚKE TVARI KAO INHIBITORI FGFR-a
US8131527B1 (en) 2006-12-22 2012-03-06 Astex Therapeutics Ltd. FGFR pharmacophore compounds
EP2158471A1 (en) 2007-06-25 2010-03-03 Qinetiq Limited Heater suitable for use in a preconcentrator device
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
WO2009056886A1 (en) 2007-11-01 2009-05-07 Astrazeneca Ab Pyrimidine derivatives and their use as modulators of fgfr activity
WO2009076660A2 (en) * 2007-12-13 2009-06-18 Tyratech, Inc. Organic absorbent material and uses thereof
CL2008003675A1 (es) * 2007-12-13 2009-03-20 Wyeth Corp Compuestos derivados de 5-alquil o alquenil 3-cianopiridinas, procedimiento de preparacion, composicion farmaceutica, util para reducir la actividad incrementada de una enzima en un mamifero, en donde dicha enzima es una proteina quinasa, destinado al tratamiento de la inflamacion, asma, colitis, esclerosis multiple, soriasis, artritis reumatoide.
BRPI0913031A2 (pt) 2008-05-23 2019-11-26 Novartis Ag derivados de quinolina e quinoxalinas como inibidores de proteína tirosina quinase, seus usos e processo de fabricação, bem como composições farmacêuticas e combinação que os compreende
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
MX2010014234A (es) 2008-06-19 2011-03-25 Astrazeneca Ab Compuestos pirazol 436.
CA2748276A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted pyrazolo [3, 4-b] pyridine compounds
CA2748174A1 (en) 2008-12-30 2010-07-08 Arqule, Inc. Substituted 1h-pyrazolo[3,4-d]pyrimidine-6-amine compounds
EP2379506B1 (en) 2008-12-30 2015-09-02 ArQule, Inc. Substituted 5,6-dihydro-6-phenylbenzo[f]isoquinolin-2-amine compounds
US9002427B2 (en) 2009-03-30 2015-04-07 Lifewave Biomedical, Inc. Apparatus and method for continuous noninvasive measurement of respiratory function and events
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
FR2947546B1 (fr) 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
EP2270043A1 (en) 2009-07-03 2011-01-05 Sanofi-Aventis Extracellular allosteric inhibitor binding domain from a tyrosine kinase receptor
KR101529767B1 (ko) 2009-08-07 2015-06-17 추가이 세이야쿠 가부시키가이샤 아미노피라졸 유도체
WO2011051425A1 (en) 2009-10-30 2011-05-05 Novartis Ag N-oxide of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea
AR079257A1 (es) 2009-12-07 2012-01-04 Novartis Ag Formas cristalinas de 3-(2,6-dicloro-3-5-dimetoxi-fenil)-1-{6-[4-(4-etil-piperazin-1-il)-fenil-amino]-pirimidin-4-il}-1-metil-urea y sales de las mismas
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
FR2962437B1 (fr) 2010-07-06 2012-08-17 Sanofi Aventis Derives d'imidazopyridine, leur procede de preparation et leur application en therapeutique
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
FR2984325A1 (fr) 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
AU2013210403B2 (en) 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
PT2821402T (pt) 2012-02-28 2019-10-02 Kotobuki Pharmaceutical Co Ltd Composto aromático heterocíclico que contém nitrogénio
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
ES2984771T3 (es) 2012-06-13 2024-10-31 Incyte Holdings Corp Compuestos tricíclicos sustituidos como inhibidores de FGFR
RU2019102203A (ru) 2012-07-11 2019-03-05 Блюпринт Медсинс Корпорейшн Ингибиторы рецептора фактора роста фибробластов
WO2014026125A1 (en) 2012-08-10 2014-02-13 Incyte Corporation Pyrazine derivatives as fgfr inhibitors
WO2014044846A1 (en) 2012-09-24 2014-03-27 Evotec (Uk) Ltd. 3-(aryl- or heteroaryl-amino)-7-(3,5-dimethoxyphenyl)isoquinoline derivatives as fgfr inhibitors useful for the treatment of proliferative disorders or dysplasia
WO2014048878A1 (en) 2012-09-26 2014-04-03 Evotec (Uk) Ltd. Phenyl- or pyridyl- pyrrolo[2,3b]pyrazine derivatives useful in the treatment or prevention of proliferative disorders or dysplasia
HK1210500A1 (en) 2012-09-27 2016-04-22 中外制药株式会社 Fgfr3 fusion gene and pharmaceutical drug targeting same
TWI628176B (zh) 2013-04-04 2018-07-01 奧利安公司 蛋白質激酶抑制劑

Also Published As

Publication number Publication date
NZ711101A (en) 2018-08-31
JPWO2014129477A1 (ja) 2017-02-02
TW201900168A (zh) 2019-01-01
PE20151509A1 (es) 2015-10-18
CA2901585C (en) 2019-09-24
HUE032931T2 (en) 2017-11-28
PH12015501813A1 (en) 2015-12-07
EP2960238A1 (en) 2015-12-30
EP2960238B1 (en) 2017-04-05
PT2960238T (pt) 2017-06-05
JP5600229B1 (ja) 2014-10-01
BR112015019790B1 (pt) 2020-12-01
ES2628495T3 (es) 2017-08-03
UA116794C2 (uk) 2018-05-10
TWI672140B (zh) 2019-09-21
US20140235614A1 (en) 2014-08-21
EP2960238A4 (en) 2016-08-17
TWI672139B (zh) 2019-09-21
ME02755B (me) 2018-01-20
MY178760A (en) 2020-10-20
RU2645352C2 (ru) 2018-02-21
TWI641602B (zh) 2018-11-21
AU2014219811A1 (en) 2015-09-03
HK1215949A1 (en) 2016-09-30
TW201439085A (zh) 2014-10-16
KR102050128B1 (ko) 2019-11-28
TWI672296B (zh) 2019-09-21
CN105073730A (zh) 2015-11-18
SG11201506488WA (en) 2015-09-29
SI2960238T1 (sl) 2017-07-31
JP2014237707A (ja) 2014-12-18
RS56064B1 (sr) 2017-10-31
RU2015134558A (ru) 2017-03-24
IL240623A0 (en) 2015-10-29
WO2014129477A1 (ja) 2014-08-28
SMT201700288T1 (it) 2017-07-18
KR20150118151A (ko) 2015-10-21
IL240623B (en) 2019-03-31
MX2015010698A (es) 2016-04-11
AR094812A1 (es) 2015-08-26
ZA201505941B (en) 2016-07-27
CA2901585A1 (en) 2014-08-28
US8933099B2 (en) 2015-01-13
CY1119220T1 (el) 2018-02-14
PL2960238T3 (pl) 2017-09-29
LT2960238T (lt) 2017-07-10
HRP20170873T1 (hr) 2017-09-08
TW201902889A (zh) 2019-01-16
MX361870B (es) 2018-12-18
AU2014219811B2 (en) 2017-09-28
DK2960238T3 (en) 2017-06-26
CN105073730B (zh) 2017-10-13
BR112015019790A2 (pt) 2017-07-18
TW201900169A (zh) 2019-01-01
CL2015002311A1 (es) 2016-02-05

Similar Documents

Publication Publication Date Title
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
CY1122821T1 (el) Παραγωγα 1,3-βενζοδιοξολιου ως αναστολεις εζη1 ή/και εζη2
NZ629025A (en) Naphthyridine derivatives useful as alpha-v-beta-6 integrin antagonists
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
UA118259C2 (uk) Гетероциклічні аміди як інгібітори кінази
MX2017010735A (es) Inhibidores de inhibidores del factor beta de crecimiento de transformacion (tgf-beta).
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
EA201690127A1 (ru) Состав на основе ингибиторов syk
NZ710052A (en) Novel pyrazol derivatives
IN2014DN07283A (ar)
MX2017005158A (es) Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).
PH12018501181A1 (en) Phenyl derivatives as cannabinoid receptor 2 agonists
MX2016007861A (es) Compuestos de ácido dimetilbenzoico.
MX2015017156A (es) Inhibidores de bace.
PH12020500292A1 (en) Pyridine compound substituted with azole
MX2016005993A (es) Anfifilos biscationicos y triscationicos como agentes antimicrobianos.
PH12018502012B1 (en) Griseofulvin compound
MX2015013224A (es) Inhibidores macrociclicos y biciclicos del virus de la hepatitis c.
PH12016500152A1 (en) Novel triazine derivative
MD20150103A2 (ro) Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
MX2015007309A (es) Derivado de hidantoina.
EP3769757A3 (en) Imaging histone deacetylases with a radiotracer using positron emission tomography
PH12016501645A1 (en) Aminopyrazolone derivative
MX345264B (es) Derivado de azol.